Bladder Cancer Progression Despite BCG Therapy Predicts Worse Outcomes
Progression on bacillus Calmette-Guérin (BCG) likely represents a biologically aggressive disease state as well as diagnostic delay, according to investigators.
Immunotherapy
First-Line Immunotherapy, Chemotherapy for mUC of the Bladder Offer Similar Survival
Real-world data validate recently reported findings from clinical trials.
Second-Line Immunotherapy May Improve Survival in Mesothelioma
Immune checkpoint inhibitors prolonged survival when compared with chemotherapy.
Response Endpoints Deemed ‘Poor Surrogates’ for Overall Survival in Trials of Immune Checkpoint Inhibitors
Response endpoints were not strongly correlated with overall survival at the trial level.
No Benefit With Ipilimumab Plus Nivolumab in Previously Treated Squamous Non-Small Cell Lung Cancer
There was no improvement in progression-free or overall survival.
Can Patients With Multiple Myeloma Boost Their Immunity?
Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival
Immune-related adverse events were associated with improved survival outcomes.
Immunotherapy, Chemotherapy Combination Improves Survival in Advanced Esophageal Cancer
Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.
Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Preexisting Autoimmune Disease Increases Incidence of irAEs With PD-1 Immunotherapy for Advanced Cancer
Study findings demonstrate the rates of immune-related adverse events and flares of the underlying disorders in this patient population.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...